Introduction {#S0001}
============

Acute lymphoblastic leukemia (ALL) is a malignant disease in which lymphocytic B-line or T-line cells proliferate abnormally in the bone marrow and extramedullary sites. The diagnosis of ALL mainly relies on cell morphology, immunology, cytogenetics and molecular biology (MICM). According to the antigens on the surface of leukemic cell, ALL can be diagnosed and divided into different subtypes. The markers of acute B-lymphoblastic leukemia (B-ALL) include CD19, cytoplasmic CD79a, cytoplasmic CD22, CD10, surface CD22, CD24, PAX5, and TdT.[@CIT0001] Philadelphia (Ph) chromosome is involved in 90--95% of CML patients. BCR/ABL fusion protein is produced by t(9;22) fused by BCR 22q11.2 and ABL1 of 9q34.[@CIT0002],[@CIT0003] In the world, this is the first reported B-ALL female with entire ABL1 gene deletion but not BCR/ABL1 fusion.

Case Report {#S0002}
===========

A 51-year-old woman was transferred to our hospital from a local clinic. Bone marrow biopsy had confirmed the presence of B-cell precursor lymphoblastic leukemia in the local hospital. At our hospital, bone marrow cytology showed that lymphoblasts and prolymphocytes accounted for 87% of bone marrow cells ([Figure 1](#F0001){ref-type="fig"}). Flow cytometry revealed that blasts were positive for CD34, TdT, CD19, CD10. Few cells showed weakly positive and scattered expression of cytoplasmic CD79a, and MPO, Lyso, CD3 and CD138, but no expression of cytoplasmic CD56. Initial complete blood counts were as follows: a hemoglobin level of 56 g/L, a platelet count of 30\*10^9^/L and a white blood cell count of 1.5\*10^9^/L, 10.3% segmented neutrophils, 85.6% lymphocytes, 2.7% monocytes. PET/CT revealed that multiple lymphadenopathy, hepatosplenomegaly, and extensive bone marrow infiltration with high FDG. The 24 hrs unstimulated culture of bone marrow aspirates showed that all the metaphase cells, though not massive, were normal karyotypes ([Figure 2](#F0002){ref-type="fig"}). Fluorescence in situ hybridization (FISH) signals using Ph-like B-ALL probes, including IGH/CRLF2, PDGFRB, JAK2, BCR/ABL1, ABL1 and EPOR revealed that of the 100 interphase cells analyzed, 36 (36%) showed ABL1 gene deletion but no rearrangement, and the rest showed no abnormality. The FISH analysis using BCR/ABL1 and ABL1 probes confirmed the presence of nuc ish (BCR×2, ABL1×1)\[35/100\], (ABL1×1)\[36/100\] ([Figure 3](#F0003){ref-type="fig"}). The signals indicating BCR-ABL fusion did not appear.Figure 1(**A**) The new diagnosis of bone marrow smears showed that lymphoblast and prolymphocyte accounted for 87%. (**B**) The Myelogram showed no blast cell after the systemic chemotherapy.Figure 2Chromosome study showing a normal female karyotype, 46,XX.Figure 3(**A**) FISH using BCR-ABL dual-color, dual-fusion translocation probe at diagnosis. Two green signals (BCR gene) are present, but only one red signal (ABL gene) is found. (**B**) FISH using ABL1 probe at diagnosis. Green signal represents 5ʹABL1 and red signal represents 3ʹABL1.

Before beginning therapy, the second round of FISH analysis using BCR/ABL1 probe identified ABL1 deletion in up to 80% of the cells. Then, we proceeded copy number variations (CNV) analysis based on next-generation sequencing (NGS), belong to CNV-Seq, which covered the targeted region of 118 sequenced genes with a total length of 215kb. CNV analysis found the reduction in the copies of ABL1 gene on the long arm of chromosome 9, EVT6 gene on the short arm of chromosome 12 and DLEU2 gene on the long arm of chromosome 13; the increase in the copies of RET, PTEN, NT5C2 and SMC3 on the long arm of chromosome 10 ([Figure 4](#F0004){ref-type="fig"}). The further analysis of CNV according to the sequencing depth of NGS indicated about 90% deletion of ABL1 gene and combined with FISH considerations, ABL1 deletion is loss of heterozygosity. It is worth mentioning that the deletions of exons are 2--10 (corresponding transcript: NM_005157), that is, all exons of ABL1 involved in this panel.Figure 4Copy number variations (CNV) analysis based on next-generation sequencing (NGS). Log2\>0.5: gene copy number significantly increased; Log2\<-0.5: gene copy number significantly deleted. The reduction in the copies of ABL1 gene on the long arm of chromosome 9, EVT6 gene on the short arm of chromosome 12 and DLEU2 gene on the long arm of chromosome 13; the increase in the copies of RET, PTEN, NT5C2 and SMC3 on the long arm of chromosome 10.

Subsequently, the patient received one cycle of IVCLP chemotherapy (Idarubicin, Vindesine, Cyclophosphamide, Pegaspargase and Dexamethasone), achieving obvious clinical remission and negative results in bone marrow biopsy ([Figure 1](#F0001){ref-type="fig"}). After six regimens of chemotherapy, the patient has been in continuous remission till now.

Discussion {#S0003}
==========

Unlike ABL1 deletion on derivative chromosome 9 generated by t(9;22),[@CIT0004]--[@CIT0007] entire ABL1 gene deletion without BCR/ABL1 rearrangement is still a rare phenomenon. Up to now, only five cases have been reported, all in males aged 7--37 years ([Table 1](#T0001){ref-type="table"}).[@CIT0008]--[@CIT0011] The five previously reported patients did not perform CNV based on NGS; however, it is not difficult to speculate that their ABL1 deletion should also be loss of heterozygosity. Of note, this is the first reported female case. Whether males are more prone to entire ABL1 deletion needs further verifications. Although the effect of ABL1 deletion on leukemogenesis is still unclear, we speculate that ALL may occur with the mutation of ABL1 gene and the probable pathogenesis can be analyzed as follows according to the previous literature.Table 1Reported Cases of ABL1 Deletion Without BCR/ABL1 Rearrangement in Precursor B-Cell Acute Lymphoblastic LeukemiaAuthorGenderAge (Year)Immunophenotype ResultKaryotypeFISHTherapeutic RegimenEfficacyLee et al, 2003[@CIT0011]Male7Pre-B cell\
ALL46,XY\[20\]One ABL1 signal (81%)NANALee et al, 2003[@CIT0011]Male36Early pre-B\
cell ALL46,XY\[20\]One ABL1 signal (95%)NANAHuh et al, 2008[@CIT0010]Male37CD19,CD34,CD79a, CD13,HLA-DR,TdT (Pre-B cell ALL)46,XY,add(9)(p22),add(16)(p13.3)\[13\]/46,XY\[7\]One ABL1 signal (76%), ETV6 rearrangement (81%)Cyclophosphamide, vincristine, adriamycin, dexamethasone (CVAD)CRLo et al, 2009[@CIT0009]Male37CD19,CD34,CD20,CD22,HLA-DR, TdT(Pre-B cell ALL)Initial diagnosis: 45,XY,del(2)(q21q31),-7,add(19)(p13.3)\[cp10\]/46,XY\[10\].\
First relapse:46,XY.\
Follow-up 3 months: 46,XY.\
Second relapse:46,XY.Initial diagnosis: Not performed.\
First relapse: Not performed.\
Follow-up 3 months: nuc ish\
(ABL1 x 1),(BCR x 2)\[107/200\].\
Second relapse: nuc ish 1p(CEB108/T7 x 3), 1q(D1S3738 x 1)\[96/200\]/2q24.3(RP11-194P8 x 1),(D2Z1 x 2)\[108/200\]/7q31(D7S48 x 1), (D7Z1 x 1)\[100/200\]/9p21(p16 x 0),(CEP9 x 2)\[90/200\]/11q22.3(RP11-78O16 x 1), 11q22.3\
(ATM x 2)\[102/200\]/17p13.3(LIS1 x 1), 17q21.1(RARA x 2)\[80/200\]/13q14(LSI 13 x 2),21q22(LSI 21 x 3)\[90/200\]Cyclophosphamide, vincristine, adriamycin, dexamethasone (CVAD)CRKim et al, 2010[@CIT0008]Male16CD19,CD34,CD20,CD10,HLA-DR, TdT (Pre-B cell ALL)46,XY\[10\]nuc ish (ABL1 x 1),(BCR x 2)\[181/223\],(TEL,AML1) x 2\[209/209\],(MLL x 2)\[302/304\]NACRThis caseFemale51CD34,TdT,CD19, CD10,CD79a, MPO,Lyso,CD3,CD138 (Pre-B cell ALL)46,XX\[9\]Initial diagnosis: nuc ish (BCR×2,ABL1×1)\[35/100\], (ABL1×1)\[36/100\]\
Second round of FISH analysis before therapy: One ABL1 signal (80%)Idarubicin, Vindesine, Cyclophosphamide, Pegaspargase, Dexamethasone (IVCLP)CR[^2]

c-Abl, one member of ABL family, can be provoked through a variety of cellar signals in response to stimuli.[@CIT0012],[@CIT0013] In normal physiological conditions, c-Abl is retained in the cytoplasm to interact with other protein. Upon DNA-mediated breaks, c-Abl is activated in the cell nucleus, a process that requires the ATM checkpoint kinase to be phosphorylated at c-Abl Ser465.[@CIT0014],[@CIT0015] Activated c-Abl protects p53 from proteasomal degradation through interactions with HDM2.[@CIT0016] HDM2, human Mdm2, is a primary negative regulator of p53 through its E3 ligase activity.[@CIT0017],[@CIT0018] Actually, c-Abl counteracts the degradation of p53 by HDM2 and inhibit the transcription and apoptosis of p53.[@CIT0019] In this mechanism, the phosphorylation of c-Abl is indispensable. c-Abl interacts with HDM2 to phosphorylate HDM2 at Tyr394. In turn, the phosphorylation of HDM2 Tyr394 disrupts the ability of HDM2, leading to stabilization of p53 and p53-mediated tumor apoptosis.[@CIT0020],[@CIT0021] These findings revealed that the phosphorylation of HDM2 by c-Abl activated kinase alters the signal transduction of Hdm2-p53, promoting the stabilization and activation of P53 ([Figure 4](#F0004){ref-type="fig"}). In addition, RING finger proteins HDMX originally isolated as a protein interacting with the tumor suppressor p53, shares significant structural and functional similarity with HDM2.[@CIT0022] Although HDMX also binds to p53, HDMX does not induce p53 degradation directly, due to the lack of E3 ubiquitin ligase activity on p53. c-Abl phosphorylation of HDM2 increases the formation of heterodimer HDM2-HDMX proximal to the RING domain of HDM2, and creates a junction between HDMX and HDM2 N-termini. This junction switches HDM2-mediated ubiquitination away from p53 to heterodimer formation, ultimately promoting p53 activation[@CIT0023]--[@CIT0025] ([Figure 5](#F0005){ref-type="fig"}). Therefore, ABL1 deletion in B-ALL may repress the activity and stability of tumor suppressor gene.Figure 5On one hand, the phosphorylation of HDM2 by c-Abl activated kinase alters the signal transduction of Hdm2-p53, promoting the stabilization and activation of P53. On the other hand, c-Abl phosphorylation of Hdm2 increases Hdm2-HdmX complex formation and promotes MDM2-directed MDMX ubiquitination, promoting p53 activation.

Apart from p53, c-Abl also regulates p73, a structural and functional homologue of p53, through the signaling path of ATM--cAbl--YAP1--p73.[@CIT0013] The activated c-Abl phosphorylates Yes-Associated Protein 1(YAP1), which is a key co-activator of p73. YAP1 transfers its own co-activator function from proliferation-driving TEAD transcription factors to p73, and then promote the transcription of apoptosis-driving genes ([Figure 6](#F0006){ref-type="fig"}). YAP1 can also keep p53 from Tyr357 phosphorylation.[@CIT0026] The specific mechanism remains to be explored.Figure 6The phosphorylation of YAP1 by c-Abl activated kinase transfers its co-activator function from proliferation-driving TEAD transcription factors to p73, and then promote the transcription of apoptotic target genes.

ABL also suppresses tumor development through contextually regulating oncogenic transforming growth factor-β (TGF-β) signaling. TGF-β is either facilitative or inhibitive for tumorigenesis. In tumor microenvironment, TGF-β becomes tumor-facilitative.[@CIT0027] There are findings proposing that ABL activation can block tumor-promoting microenvironmental signals and restore a tumor-suppressing microenvironment. It is well known that matrix metalloproteinases (MMPs) can modify the extracellular matrix (ECM) to allow malignant cells to penetrate into the normal tissue.[@CIT0028] TGF-β up-regulates MMPs significantly, in especial MMP-9 and MMP-13, to enhance the invasion of tumor cells.[@CIT0029],[@CIT0030] ABL activation, however, can suppress the expression and secretion of MMPs through inhibiting TGF-β signaling ([Figure 7](#F0007){ref-type="fig"}). Therefore, this may be another mechanism to explain the occurrence of malignant tumors in patients with ABL1 deletion.Figure 7TGF-β signaling stimulates the secretion and activation of matrix metalloproteinases (MMPs) to remodel the extracellular matrix (ECM), then allowing malignant cells to penetrate the normal tissue. However, ABL activation can suppress the expression and secretion of MMPs through inhibiting TGF-β signaling and protect tumor cells from invading the tissue.

Furthermore, ABL deletion on derivative chromosome 9 is associated with poor prognosis of patients with CML.[@CIT0031] The patients with ABL or BCR deletion showed shorter survival than those with normal ABL and BCR in CML.[@CIT0007] The mechanisms are not well known. An England research reported that the BCR 3ʹregion encodes a GTPase-activating protein for p21^rac^ (a Ras-related GTP-binding protein) to promote the proliferation of cells associated with RAS. The activity of GTPase-activating protein is inhibited by the combination with p21^rac^ and GTPase-activating protein.[@CIT0032] Thus, deletion of BCR 3ʹregion may promote the proliferation of tumor cells. These researches also speculated that certain tumor-related genes may locate near the ABL breakpoint and play a role in the inhibition of tumor progression.[@CIT0033] This may explain the short survival in patients with ABL deletion. On the other hand, the remaining alleles are susceptible to injure and the function of the tumor suppression may be disrupted after ABL deletion, so disease progression can be promoted as a result. In the present case, the patient's long-term prognosis should be followed up, although she is now in complete remission.

In summary, entire ABL1 deletion without BCR/ABL1 fusion is a rare phenomenon in ALL patients, especially in females. ABL1 deletion correlates with the pathogenesis and prognosis of ALL. On one hand, ABL deletion negatively influences the activation of P53 and P73, and allows tumor cells to invade normal tissues through TGF-β signaling pathway. However, the clinical significance of ABL1 deletion in ALL development remains to be clarified with more cases.
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